Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
TWST submitted a Form 144 notice relating to 2,500 shares of Common Stock tied to a restricted stock vesting event dated 02/07/2024. The filing lists prior sales of 1,000 shares on 04/01/2026 for $51,000, 500 shares on 04/27/2026 for $30,915, and 500 shares on 05/26/2026 for $30,520.
TWST: Notice of proposed sales under Rule 144 by Emily M. Leproust. The filing lists multiple proposed dispositions of Common Stock by Emily M. Leproust, including a sale of 24,282 shares for $1,580,246.60 on 05/26/2026 and earlier listed transactions in March–May 2026. The filing also notes an option granted 09/29/2017.
Form 144 filing reports a planned sale of 24,282 shares of Common Stock on 05/26/2026. The filing lists prior open-market dispositions by Emily M. Leproust during the past three months, including 2,423 shares on 03/06/2026, 8,061 shares on 04/22/2026, and 6,888 shares on 05/21/2026.
Twist Bioscience Corp SVP of Human Resources Paula Green reported an open-market sale of 1,399 shares of common stock at $53.257 per share. According to the footnote, this transaction was a mandated “sell to cover” to satisfy tax withholding obligations tied to vesting Restricted Stock Units, rather than a discretionary trade. After the sale, she directly holds 121,589 shares of Twist Bioscience common stock.
Twist Bioscience Corp President and COO Patrick John Finn reported a mandated sale of 4,160 shares of common stock. The shares were sold on May 21, 2026 at an average price of $53.257 per share to cover tax withholding obligations from vesting Restricted Stock Units.
According to the disclosure, this was a required "sell to cover" transaction under the company’s equity incentive plans and did not represent a discretionary trade by Finn. After the sale, he directly held 274,804 shares of Twist Bioscience common stock.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 1,642 shares of Common Stock at $53.257 per share. According to the filing, these shares were sold solely to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans, pursuant to a mandated “sell to cover” election rather than a discretionary trade. After this transaction, Cho directly holds 134,299 shares of Twist Bioscience common stock.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported an insider stock sale tied to tax withholding. On May 21, 2026, he sold 688 shares of common stock at $53.257 per share in an open-market transaction.
According to the footnote, the shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans, and did not represent discretionary trading. After this mandated “sell to cover” transaction, Werner directly holds 48,986 common shares of Twist Bioscience.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a mandated sale of 6,888 shares of Common Stock on May 21, 2026 at an average price of $53.257 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans, and the transaction did not represent a discretionary trade by the CEO. Following this transaction, Leproust directly held 846,872 shares of Twist Bioscience Common Stock and retained employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share, expiring on August 31, 2030.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,019 shares of common stock at an average price of $53.257 per share. According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans and were not discretionary trades. After this transaction, Laponis directly holds 116,675 shares of Twist Bioscience common stock.
TWST submitted a Form 144 notice reporting the proposed sale of 800 shares of Common Stock arising from restricted stock vesting on 05/22/2026. The filing lists several prior dispositions in 2026 by Robert F. Werner, including sales of 1,693, 246, 164, 4,961, and 688 shares on various dates with dollar proceeds shown. The filing names Fidelity Brokerage Services LLC as the broker and classifies the 800 shares as compensation-related shares.